Loading
A phase 3 trial of Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide and Carboplatin in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting.
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer is a phase 3 interventional study registered as NCT06112379 by AstraZeneca, with 1902 participants enrolled, started 2023-11-14 and due to reach its primary completion in 2028-11-20. Interventions recorded: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin and Cyclophosphamide.
Shares Epirubicin, Daiichi Sankyo, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Epirubicin, Early triple-negative breast cancer, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Epirubicin, Doxorubicin, Cyclophosphamide, Pembrolizumab and the tag pipeline.
Shares Datopotamab deruxtecan, Durvalumab, AstraZeneca, Carboplatin and the tag pipeline.
Shares Datopotamab deruxtecan, Daiichi Sankyo, AstraZeneca, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Olaparib, Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Datopotamab deruxtecan, Durvalumab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), AstraZeneca and the tag pipeline.
Shares Olaparib, Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.